scholarly journals Fixed-dose valsartan + hydrochlorothiazide combination therapy compared with amlodipine monotherapy in hypertensive patients with additional cardiovascular risk factors: The vast study

2005 ◽  
Vol 18 (5) ◽  
pp. A72-A73
Author(s):  
L RUILOPE ◽  
E MALACCO ◽  
Y KHDER ◽  
G BONNER ◽  
D HEINTZ
Keyword(s):  
Risk Factors ◽  
Cardiovascular Risk ◽  
Combination Therapy ◽  
Cardiovascular Risk Factors ◽  
Fixed Dose ◽  
Hypertensive Patients

scholarly journals Exercise versus fixed-dose combination therapy for cardiovascular risk factors control and atherosclerotic disease prevention: a network meta-analysis protocol

BMJ Open ◽  
2020 ◽  
Vol 10 (7) ◽  
pp. e036734
Author(s):  
Diana P Pozuelo-Carrascosa ◽  
Iván Cavero-Redondo ◽  
Ruben Fernández Rodríguez ◽  
Carlos Pascual Morena ◽  
Irene Sequí-Domínguez ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cardiovascular Risk ◽  
Combination Therapy ◽  
Physical Exercise ◽  
Cardiovascular Risk Factors ◽  
Cardiovascular Mortality ◽  
Meta Analysis ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Dose Combination

IntroductionDespite the consistent evidence of the benefits of physical activity on preventing atherosclerotic cardiovascular diseases (ASCVD) and some cardiovascular risk factors, such as hypertension and dyslipidaemia, the prescription of drugs remains the most widely used approach to prevent ASCVD in clinical settings. The purpose of this study protocol is to provide a meta-synthesis methodology for comparing the effect of fixed-dose combination therapy and physical exercise on controlling cardiovascular risk factors and preventing ASCVD.Methods and analysisThis protocol follows the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols and the recommendations of the Cochrane Collaboration Handbook. We plan to conduct a computerised search in Medline, Web of Science, Embase, Cochrane Database of Systematic Reviews and SPORTDiscus from inception to May 2020 for studies testing the effectiveness of physical exercise or fixed-dose combination drug therapy in preventing ASCVD, all-cause and cardiovascular mortality and controlling some cardiovascular risk factors (hypertension and dyslipidaemia). Since performing network meta-analyses (NMA) is a statistical approach that allows direct and indirect comparisons of interventions, where sufficient studies are included, we plan to perform the following NMA comparing the effect of fixed-dose combination therapy and physical exercise interventions on (1) improving lipid profile, (2) reducing blood pressure, (3) preventing cardiovascular events and all-cause and cardiovascular mortality and (4) improving compliance with the therapeutic strategy and reducing adverse events.Ethics and disseminationEthical approval will not be needed because data included in the NMA will be extracted from published trials that meet accepted ethical standards. The results will be published in academic peer-reviewed journals, and the evidence gathered by this project could be included in the preventive cardiovascular disease guidelines.PROSPERO registration numberCRD42019122794.

Pulmonal-arterielle Hypertonie: Initiale Kombinationstherapie bei atypischen Patienten nicht erzwingen

2021 ◽  
pp. 1-2
Author(s):  
Simon-Dominik Herkenrath
Keyword(s):  
Risk Factors ◽  
Cardiovascular Risk ◽  
Targeted Therapy ◽  
Combination Therapy ◽  
Cardiovascular Risk Factors ◽  
Triple Therapy ◽  
Gold Standard ◽  
Arterielle Hypertonie ◽  
Pulmonal Arterielle Hypertonie ◽  
Pulmonary Arterial

<b>Background:</b> Background: Although combination therapy is the gold standard for patients with pulmonary arterial hypertension (PAH), some of these patients are still being treated with monotherapy. <b>Methods:</b> We conducted a retrospective analysis at four German PH centres to describe the prevalence and characteristics of patients receiving monotherapy. <b>Results:</b> We identified 131 incident PAH patients, with a mean age of 64 ± 13.8 years and a varying prevalence of comorbidities, cardiovascular risk factors and targeted therapy. As in other studies, the extent of prescribed PAH therapy varied with age and coexisting diseases, and younger, so-called «typical» PAH patients were more commonly treated early with combination therapy (48% at 4–8 months). In contrast, patients with multiple comorbidities or cardiovascular risk factors were more often treated with monotherapy (69% at 4–8 months). Survival at 12 months was not significantly associated with the number of PAH drugs used (single, dual, triple therapy) and was not different between «atypical» and «typical» PAH patients (89% vs. 85%). <b>Conclusion:</b> Although «atypical» PAH patients with comorbidities or a more advanced age are less aggressively treated with respect to combination therapy, the outcome of monotherapy in these patients appears to be comparable to that of dual or triple therapy in «typical» PAH patients.

scholarly journals COMPARATIVE ASSESSMENT OF PREDICTIVE VALUE OF TOTAL CARDIOVASCULAR RISK FACTORS FOR PROGNOSIS OF STROKE AND HEART ATTACK IN HYPERTENSION

2009 ◽  
Vol 15 (6) ◽  
pp. 665-670
Author(s):  
A. A. Dzizinskij ◽  
G. M. Sinkova ◽  
V. V. Sprach ◽  
A. V. Sinkov
Keyword(s):  
Risk Factors ◽  
Cardiovascular Risk ◽  
Cardiovascular Risk Factors ◽  
Predictive Value ◽  
Heart Attack ◽  
Comparative Assessment ◽  
Predictive Values ◽  
Hypertensive Patients ◽  
Design And Methods

Objective. To assess predictive value of total cardiovascular risk (CV) factors for prognosis of stroke and heart attack in hypertension. Design and methods. 841 hypertensive patients (197 men, 644 women) 19-95 years old were examined. Results. It was established that total CV risk factors have different predictive values. The majority of factors were more valuable for prognosis of heart attack, but not for stroke.

Sign in / Sign up

Export Citation Format

Share Document